The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

(2017) Silvia La Monica et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials

(2017) Nandini Dey et al.   PHARMACOLOGY & THERAPEUTICS

Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells

(2017) Mara A. Bonelli et al.   NEOPLASIA

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR- Activating Mutation

(2016) Silvia La Monica et al.   Journal of Thoracic Oncology

Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt

(2016) Jinfang Zhang et al.   MOLECULAR CELL

Palbociclib and Letrozole in Advanced Breast Cancer

(2016) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting the RB-E2F pathway in breast cancer

(2016) J Johnson et al.   ONCOGENE

Progress with palbociclib in breast cancer: latest evidence and clinical considerations

(2016) Andrea Rocca et al.   Therapeutic Advances in Medical Oncology

Metabolic reprogramming: the emerging concept and associated therapeutic strategies

(2015) Go J. Yoshida   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

(2015) Richard S Finn et al.   LANCET ONCOLOGY

Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP

(2015) Liangliang Shen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions

(2014) Agnieszka K Witkiewicz et al.   BREAST CANCER RESEARCH

CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment

(2014) A. DeMichele et al.   CLINICAL CANCER RESEARCH

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

(2014) Daniele Cretella et al.   Molecular Cancer

Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling

(2013) Claudia Fumarola et al.   BREAST CANCER RESEARCH AND TREATMENT

QM-FISH analysis of the genes involved in the G1/S checkpoint signaling pathway in triple-negative breast cancer

(2013) Sheng Zhang et al.   TUMOR BIOLOGY

Re-thinking cell cycle regulators: the cross-talk with metabolism

(2013) Lluis Fajas   Frontiers in Oncology

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer

(2011) Yoshimi Arima et al.   INTERNATIONAL JOURNAL OF CANCER

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines

(2011) Roberta R Alfieri et al.   Molecular Cancer

Metabolism and proliferation share common regulatory pathways in cancer cells

(2010) V Fritz et al.   ONCOGENE

Akt and c-Myc Differentially Activate Cellular Metabolic Programs and Prime Cells to Bioenergetic Inhibition

(2009) Yongjun Fan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation

(2008) Ralph J. DeBerardinis et al.   Cell Metabolism

Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines

(2008) A. Cavazzoni et al.   MOLECULAR CANCER THERAPEUTICS